Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.55 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.44 |
| ▸ | GPR183 | P32249 | 2/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | PLG | P00747 | 1/20 | 0.43 |
| ▸ | PLAU | P00749 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1156450 | 0.86 | FLT3 (0.57) | HRH4MAP2K1FLT3 | |
| SCHEMBL30920180 | 0.84 | KDM4E (0.59) | HRH4 | |
| SCHEMBL1647680 | 0.84 | KDM4E (0.59) | HRH4 | |
| SCHEMBL20617945 | 0.82 | HRH4 (0.51) | HRH4DRD4GPR183 | |
| Hydrochloric Acid SCHEMBL28903044 | 0.82 | KDM4E (0.58) | HRH4 | |
| SCHEMBL20267033 | 0.82 | HRH4 (0.55) | HRH4DRD4GPR183FLT3 | |
| SCHEMBL2730304 | 0.82 | HRH4 (0.58) | HRH4DRD4GPR183FLT3 | |
| SCHEMBL3678805 | 0.80 | HRH4 (0.54) | HRH4FLT3PLGPLAU | |
| SCHEMBL31207838 | 0.80 | HRH4 (0.54) | HRH4FLT3PLGPLAU | |
| SCHEMBL19329742 | 0.80 | HRH4 (0.56) | HRH4MAP2K1FLT3PLGPLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4601635-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | Maze Therapeutics, Inc. (US) | 2025-08-20 | — | — | EP | disclosed |
| CN-118359610-A | MENIN-MLL interaction inhibitors | 生命医药有限责任公司 | 2024-07-19 | — | — | CN | disclosed |
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | HERCULES CAPITAL, INC., AS AGENT | 2024-06-20 | — | — | US | disclosed |
| WO-2024081748-A2 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | MAZE THERAPEUTICS, INC. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | VITAE PHARMACEUTICALS, LLC (US) | 2024-04-18 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | VITAE PHARMACEUTICALS, LLC (US) | 2023-08-29 | — | — | US | disclosed |
| EP-4230627-A2 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| EP-4230627-A2 | INHIBITORS OF THE MENIN-MLL INTERACTION | Vitae Pharmaceuticals, LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-106117205-A | Pyrazolo spiral shell ketone derivatives as S-acetyl-coenzyme-A carboxylase inhibitor class | 辉瑞大药厂 | 2016-11-16 | — | — | CN | disclosed |
| EP-2699576-B1 | PYRAZOLOSPIROKETONE DERIVATIVES FOR USE AS ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER (US) | 2015-12-09 | — | — | EP | disclosed |
| US-20150336958-A1 | SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-11-26 | — | — | US | disclosed |
| US-20150112068-A1 | SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2015-04-23 | — | — | US | disclosed |
| US-20140323730-A1 | SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER (US) | 2014-10-30 | — | — | US | disclosed |
| US-8802688-B2 | Substituted acetyl-coa carboxylase inhibitors | PFIZER INC. (US) | 2014-08-12 | — | — | US | disclosed |
| EP-2699576-A1 | PYRAZOLOSPIROKETONE DERIVATIVES FOR USE AS ACETYL - COA CARBOXYLASE INHIBITORS | Pfizer Inc (US) | 2014-02-26 | — | — | EP | disclosed |
| WO-2012143813-A1 | PYRAZOLOSPIROKETONE DERIVATIVES FOR USE AS ACETYL - COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2012-10-26 | — | — | WO | disclosed |
| US-20120270893-A1 | SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2012-10-25 | — | — | US | disclosed |
| WO-1997008167-A1 | 5HT2C AND 5HT2B ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336958-A1 | SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, ACAT1 | HRH4 2115/4885MAP2K1 4156/4885DRD4 4856/4885 |
| US-20150112068-A1 | SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, ACAT1 | HRH4 2115/4885MAP2K1 4156/4885DRD4 4856/4885 |
| US-11739085-B2 | Inhibitors of the menin-MLL interaction | MLLT1, MEN1, MLLT3 | HRH4 2719/4885MAP2K1 1260/4885DRD4 4777/4885 |
| US-20140323730-A1 | SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, ACAT1 | HRH4 1899/4885MAP2K1 4155/4885DRD4 4844/4885 |
| US-20240124447-A1 | INHIBITORS OF THE MENIN-MLL INTERACTION | MLLT1, MEN1, MLLT3 | HRH4 2719/4885MAP2K1 1260/4885DRD4 4777/4885 |
| US-20240199546-A1 | INHIBITORS OF SOLUTE CARRIER FAMILY 6A MEMBER 19 (SLC6A19) AND METHODS OF USE THEREOF | SLC6A19, SLC2A9, SLC6A3 | HRH4 2480/4885MAP2K1 4562/4885DRD4 1104/4885 |
| US-20120270893-A1 | SUBSTITUTED ACETYL-COA CARBOXYLASE INHIBITORS | ACACA, ACACB, ACAT1 | HRH4 1899/4885MAP2K1 4155/4885DRD4 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.